Tennessee CBD Bill Passed Unanimously by Legislature

The Tennessee Legislature has passed a bill to allow the medical use of cannabidiol (CBD) after FDA approval.

House Bill 694 passed the Senate earlier this month with a 33 to 0 vote, and today passed the House with a vote of 90 to 0. It will now be sent to Governor Bill Haslam for consideration; Haslam has the option of signing it into law, allowing it to become law without his signature, or vetoing it (though a veto could be overridden by a 2/3rds vote in the legislature).

House Bill 694 excludes from the state’s definition of marijuana any “cannabidiol product approved as a prescription medication by the United States food and drug administration [FDA]”.

Read moreTennessee CBD Bill Passed Unanimously by Legislature

Trump Administration Confirms Marijuana Legalization Advocate Being Considered to Head FDA

Sean Spicer, President Donald Trump’s Press Secretary, has confirmed previous reports that Jim O’Neil is being considered to lead the Food and Drug Administration.

O’Neil is not only a strong supporter of legalizing marijuana, he has actively worked towards it as a Board of Directors member for the Coalition for Cannabis Policy Reform, which helped legalized cannabis in California.

According to Spicer, both O’Neil and biotech executive Balaji Srnivasan “are being considered” for head of the FDA.

Both O’Neil and Srnivasan have connections with billionaire Peter Thiel, who co-founded Paypal and was an early investor in Facebook. Thiel is a supporter of Donald Trump and also supports legalizing marijuana.

Read moreTrump Administration Confirms Marijuana Legalization Advocate Being Considered to Head FDA

Trump Considering Cannabis Legalization Advocate to Head FDA

fdaPresident-elect Donald Trump is considering Jim O’Neil to head the Food and Drug Administration (FDA), according to Bloomberg News.

O’Neil is a supporter of legalizing cannabis, and has actively worked towards it; he previously served on the Board of Directors for the Coalition for Cannabis Policy Reform, which worked to legalized cannabis in California.

O’Neil is also a proponent of a concept he calls the “progressive approval” of medicines.

Read moreTrump Considering Cannabis Legalization Advocate to Head FDA

F.D.A. Approves New Phase 3 Studies for Ecstasy as PTSD Treatment

EcstasyThe Food and Drug Administration has given approval to Phase 3 clinical trials of MDMA (ecstasy) for the treatment of post traumatic stress disorder (PTSD). This is the final step before the potential approval of ecstasy as a prescription drug.

The move comes after several successful Phase 2 studies of ecstasy, which included 130 PTSD patients. These were conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The new research will include at least 230 participants and will also be conducted by MAPS.

Read moreF.D.A. Approves New Phase 3 Studies for Ecstasy as PTSD Treatment

FDA Gives Fast Track Approval to Cannabis Medicine for Newborns

Baby is holding father's finger for the first timeGW Pharmaceuticals, a biopharmaceutical company with a focus on cannabinoid-based medicines, has received fast track approval from the U.S. Food and Drug Administration (FDA) for a medicine designed to treat newborns deprived of oxygen during childbirth, which can lead to brain damage and death.

The FDA gave approval to an intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy (NHIE), which is a form of acute or sub-acute brain injury caused by asphyxia that occurs during birth. The medicine has already received approval from the European Medicines Agency to treat perinatal asphyxia, an alternate term to describe the same condition as NHIE.

Read moreFDA Gives Fast Track Approval to Cannabis Medicine for Newborns

Wyoming and Arkansas Governors Sign Bills to Nullify FDA Restrictions on Terminally-ill Patients

Arkansas Governorfda Asa Hutchinson and Wyoming Governor Matt Mead have both signed into law bills that nullify some FDA (Food and Drug Administration) restrictions that prevent terminally ill patients from using experimental treatments.

Senate Bill 4 (Arkansas) and Senate File 3 (Wyoming) would both allow a patient suffering from a terminal disease who has considered all other approved treatment options to try experimental treatments or drugs not yet approved by the FDA if recommended by a physician.

Read moreWyoming and Arkansas Governors Sign Bills to Nullify FDA Restrictions on Terminally-ill Patients

University of Alabama Receives FDA Approval to Produce, Administer and Study Cannabis Extracts

Cannabis tincture.
Cannabis tincture.

The University of Alabama has received approval from the Food and Drug Administration (FDA) to begin cultivating, administering and studying the impact of low-THC (tetrahydrocannabinol), high-CBD (cannabidiol) cannabis extracts on childhood and adult seizure disorders.

In April, Alabama Governor Robert Bentley signed into law Senate Bill 174 which authorizes the University of Alabama’s Department of Neurology to prescribe, produce and distribute low-THC cannabis extracts – such as cannabis oil and tinctures – to those with seizure disorders. The oil must be primarily CBD, and can contain no more than 3% THC.

Read moreUniversity of Alabama Receives FDA Approval to Produce, Administer and Study Cannabis Extracts

FDA Evaluating Cannabis for Potential Rescheduling

The U.S. Food and Drug Administration (FDA) is reviewing the evidence surrounding the safety and effectiveness of cannabisfda as a medicine in an attempt to determine whether its status as a Schedule 1 drug – which puts it alongside hard drugs such as heroin – is unwarranted, and should be changed.

“FDA conducts for Health and Human Services a scientific and medical analysis of the drug under consideration, which is currently ongoing,” FDA Press Officer Jeff Ventura told the Huffington Post. “HHS then recommends to DEA that the drug be placed in a given schedule. DEA considers HHS’ analysis, conducts its own assessment, and makes a final scheduling proposal in the form of a proposed rule.”

Read moreFDA Evaluating Cannabis for Potential Rescheduling